^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SNC103

    i
    Other names: SNC103, CAR-NK-CD19 cells, cord blood derived anti-CD19 CAR-engineered NK cells, anti-CD19 chimeric antigen receptor(CAR)-modified NK cells, F01
    Associations

    News

    Trials
    Company:
    Shanghai Simnova Bio
    Drug class:
    CD19 inhibitor, NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    5ms
    F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Shanghai Simnova Biotechnology Co.,Ltd.
    New P1 trial
    |
    cyclophosphamide • SNC103
    9ms
    F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=55, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd. | Initiation date: Jan 2024 --> Apr 2024
    Trial initiation date
    |
    cyclophosphamide • SNC103
    10ms
    F01 in the Treatment of Autoimmune Diseases (clinicaltrials.gov)
    P1, N=20, Recruiting, RenJi Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • SNC103
    10ms
    F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=55, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd.
    New P1 trial
    |
    cyclophosphamide • SNC103
    almost2years
    Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=2, Completed, Shanghai Simnova Biotechnology Co.,Ltd. | Recruiting --> Completed | N=21 --> 2 | Trial completion date: Jul 2024 --> Nov 2022 | Trial primary completion date: Jul 2023 --> Nov 2022
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • SNC103
    2years
    Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=21, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd.
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • SNC103
    over3years
    Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=27, Recruiting, Wuhan Union Hospital, China
    Clinical • New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    fludarabine IV • SNC103